The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.
More from Ned Pagliarulo
Sanofi, expanding in radiopharma, strikes a joint venture deal
No Comments
Leave a comment Cancel